Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens

Rubraca Revenues Are Shrinking

 
• By Andrew McConaghie

Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.

Downward red arrow concept

More from Business

More from Scrip